CorMedix wins US ap­proval via rarely-used path­way for drug to re­duce blood­stream in­fec­tions

The FDA on Wednes­day ap­proved CorMedix’s De­fen­cath (tau­ro­li­dine and he­parin) to re­duce catheter-re­lat­ed blood­stream in­fec­tions in adults with kid­ney fail­ure who are re­ceiv­ing chron­ic he­modial­y­sis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER